Daniel Markowitz
Stock Analyst at Evercore ISI Group
(2.86)
# 4,060
Out of 5,182 analysts
37
Total ratings
44.44%
Success rate
1.04%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMBS Rambus | Maintains: Outperform | $119 → $172 | $112.78 | +52.51% | 4 | Apr 28, 2026 | |
| RGEN Repligen | Maintains: Outperform | $170 → $140 | $117.96 | +18.68% | 6 | Apr 6, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $170 → $118 | $106.70 | +10.59% | 3 | Apr 6, 2026 | |
| TECH Bio-Techne | Maintains: In-Line | $68 → $54 | $54.45 | -0.83% | 5 | Apr 6, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $85 → $62 | $55.00 | +12.73% | 3 | Apr 6, 2026 | |
| GH Guardant Health | Maintains: In-Line | $110 → $90 | $85.51 | +5.25% | 5 | Apr 6, 2026 | |
| MMED MiniMed Group | Initiates: Outperform | $20 | $13.00 | +53.85% | 1 | Mar 31, 2026 | |
| NTRA Natera | Maintains: Outperform | $250 → $260 | $200.19 | +29.88% | 3 | Feb 27, 2026 | |
| PODD Insulet | Maintains: Outperform | $370 → $340 | $190.23 | +78.73% | 2 | Feb 19, 2026 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $390 → $320 | $299.97 | +6.68% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: In-Line | $68 | $62.19 | +9.34% | 1 | Nov 25, 2025 |
Rambus
Apr 28, 2026
Maintains: Outperform
Price Target: $119 → $172
Current: $112.78
Upside: +52.51%
Repligen
Apr 6, 2026
Maintains: Outperform
Price Target: $170 → $140
Current: $117.96
Upside: +18.68%
TransMedics Group
Apr 6, 2026
Maintains: Outperform
Price Target: $170 → $118
Current: $106.70
Upside: +10.59%
Bio-Techne
Apr 6, 2026
Maintains: In-Line
Price Target: $68 → $54
Current: $54.45
Upside: -0.83%
Inspire Medical Systems
Apr 6, 2026
Maintains: Outperform
Price Target: $85 → $62
Current: $55.00
Upside: +12.73%
Guardant Health
Apr 6, 2026
Maintains: In-Line
Price Target: $110 → $90
Current: $85.51
Upside: +5.25%
MiniMed Group
Mar 31, 2026
Initiates: Outperform
Price Target: $20
Current: $13.00
Upside: +53.85%
Natera
Feb 27, 2026
Maintains: Outperform
Price Target: $250 → $260
Current: $200.19
Upside: +29.88%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $370 → $340
Current: $190.23
Upside: +78.73%
West Pharmaceutical Services
Feb 3, 2026
Maintains: Outperform
Price Target: $390 → $320
Current: $299.97
Upside: +6.68%
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $62.19
Upside: +9.34%